US9573891B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9573891-B2 |
| Application number | US-201414907670-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 28, 2014 |
| Priority date | Jul 29, 2013 |
| Publication date | Feb 21, 2017 |
| Grant date | Feb 21, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Complexes of agomelatine and sulphonic acids of formula (I): Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.
Opening claim text (preview).
The invention claimed is: 1. A complex of agomelatine and sulphonic acids of formula (I): wherein x represents 0 or 1, and RSO 3 H represents 1,5-naphthalenedisulphonic acid or benzenesulphonic acid. 2. The agomelatine complex according to claim 1 , which is the agomelatine/1,5-naphthlenedisulphonic acid (2/1) complex. 3. The agomelatine complex according to claim 2 , having the following X-ray powder diffraction diagram expressed in terms of interplanar distance d, Bragg's angle 2 theta (expressed in °±0.2), and relative intensity: 2-Theta (°) exp. d (Å) exp. Intensity (%) 6.3716 13.87229 18.97 11.3804 7.77552 17.98 11.9227 7.42299 36.06 12.5064 7.07784 100.00 12.6590 6.99288 13.75 14.5508 6.08767 44.17 15.5658 5.69292 11.96 16.2029 5.47051 42.63 16.9421 5.23346 25.85 17.6267 5.03171 18.67 19.4300 4.56857 49.04 20.2146 4.39301 22.77 21.4353 4.14550 17.80 21.6713 4.10090 22.84 22.2180 4.00121 64.19 22.4174 3.96607 10.83 24.0749 3.69664 29.61 24.5048 3.63275 13.33 25.1744 3.53763 20.58 25.7599 3.45853 23.59 including the forms whose diffraction angles correspond to within ±0.2°. 4. The agomelatine complex according to claim 1 , which is the agomelatine/1,5-naphthlenedisulphonic acid (2/1) monohydrate complex. 5. The agomelatine complex according to claim 4 , having the following X-ray powder diffraction diagram expressed in terms of interplanar distance d, Bragg's angle 2 theta (expressed in °±0.2), and relative intensity: 2-Theta (°) exp. d (Å) exp. Intensity (%) 9.6680 9.14852 12.45 12.4885 7.08796 57.23 12.6164 7.01639 28.61 14.5042 6.10715 57.42 16.2684 5.44863 25.67 16.4624 5.38484 32.93 16.8967 5.24739 90.90 19.3772 4.58091 10.50 22.4767 3.95573 100.00 23.4111 3.79992 20.49 23.5330 3.78051 44.02 23.6735 3.75840 21.92 24.0477 3.70076 13.67 24.5716 3.62303 13.43 25.1240 3.54460 12.46 26.6602 3.34374 19.10 28.1333 3.16930 12.07 28.2443 3.15971 22.49 including, the forms whose diffraction angles correspond to within ±0.2°. 6. The agomelatine complex according to claim 1 , which is the agomelatine/benzenesulphonic acid (2/1) complex. 7. The agomelatine complex according to claim 6 , having the following X-ray powder diffraction diagram expressed in terms of interplanar distance d, Bragg's angle 2 theta (expressed in °±0.2), and relative intensity: 2-Theta (°) exp. d (Å) exp. Intensity (%) 8.0711 10.95469 35.25 12.6820
Antineoplastic agents · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Immunomodulators · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for immunological or allergic disorders · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.